Tcg Crossover Management
$4.2B 13F equity value
61 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Tcg Crossover Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ABVX | ABIVAX SA AMERICAN DEPOSITARY SHARES | 6,007,834 | $801M | 19.2% |
| TNGX | TANGO THERAPEUTICS INC | 9,081,201 | $284M | 6.8% |
| CGON | CG ONCOLOGY INC | 3,670,206 | $261M | 6.3% |
| COGT | COGENT BIOSCIENCES INC | 4,854,436 | $188M | 4.5% |
| IMVT | IMMUNOVANT INC | 4,457,988 | $172M | 4.1% |
| SYRE | SPYRE THERAPEUTICS INC | 1,900,582 | $169M | 4.1% |
| DNTH | DIANTHUS THERAPEUTICS INC | 1,676,624 | $163M | 3.9% |
| MIRM | MIRUM PHARMACEUTICALS INC | 1,062,049 | $124M | 3.0% |
| ZLAB | ZAI LAB LTD-ADR | 6,137,627 | $117M | 2.8% |
| AMLX | AMYLYX PHARMACEUTICALS INC | 6,243,812 | $112M | 2.7% |
Track Tcg Crossover Management's 13F portfolio: $4.2B in reported holdings, 61 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}